Company Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.
The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity.
ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Stephen Glover |
Contact Details
Address: 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 United States | |
| Phone | 754 231 1688 |
| Website | zyversa.com |
Stock Details
| Ticker Symbol | ZVSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001859007 |
| ISIN Number | US98987D2018 |
| Employer ID | 86-2685744 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen C. Glover | Co-Founder, Chairman, Chief Executive Officer and President |
| Peter Wolfe | Chief Financial Officer and Secretary |
| Karen A. Cashmere | Chief Commercial Officer |
| Melda Uzbil O'connell | Senior Vice President of Corporate Development |
| Dr. Pablo A. Guzman FACC, M.D. | Chief Medical Officer, Senior Vice President of Medical Affairs and Chairman of Renal Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Sep 16, 2024 | 424B5 | Filing |
| Sep 16, 2024 | 8-K | Current Report |
| Sep 10, 2024 | 424B3 | Prospectus |
| Sep 10, 2024 | 424B3 | Prospectus |
| Sep 9, 2024 | EFFECT | Notice of Effectiveness |